Lesinurad in hyperuricaemia of gout: a profile of its use in the EU
- 70 Downloads
Up to 90% of gout patients experience low uric acid (UA) excretion rather than high UA production. The selective UA reabsorption inhibitor lesinurad (Zurampic®) is an effective and generally well tolerated option for the adjunctive treatment of hyperuricaemia in patients with gout who have not achieved target serum uric acid (sUA) levels with monotherapy with an adequate dosage of a xanthine oxidase inhibitor, a class of drugs that acts on UA production. In phase 3 trials of lesinurad + allopurinol in adults with gout inadequately responsive to allopurinol, and lesinurad + febuxostat in adults with tophaceous gout, the addition of once-daily oral lesinurad enabled many patients to achieve target sUA levels, and improved clinical parameters (e.g. tophus number/size) in the long term.
The manuscript was updated from Drugs & Aging 2017;34(5):401–1 , and was reviewed by: M. Bleckwenn, Institut für Hausarztmedizin, Medizinischen Fakultät der Universität Bonn, Bonn, Germany; A.L. Gaffo, University of Alabama at Birmingham, and Rheumatology Section, Birmingham VA Medical Center, Birmingham, AL, USA; M.J. Puszczewicz, Department of Rheumatology and Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland; L. Roever, Clinical Research Department, Federal University of Uberlândia, Uberlândia, Brazil. During the peer review process, Grunenthal, the marketing-authorization holder of lesinurad, was also offered an opportunity to provide a scientific accuracy review of the data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflict of interest
H. A. Blair and E. D. Deeks are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.
- 7.Zurampic 200 mg film-coated tablets: EU summary of product characteristics. London: European Medicines Agency; 2017.Google Scholar
- 8.Zurampic® (lesinurad) tablets for oral use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2018.Google Scholar
- 9.Duzallo (allopurinol and lesinurad 200 mg/200 mg and 300 mg/200 mg) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2018.Google Scholar
- 19.Saag KG, Bardin T, So A, et al. Analysis of gout subjects receiving lesinurad and allopurinol combination therapy by baseline renal function [abstract no. 2112]. Arthritis Rheumatol. 2015;67(Suppl 10).Google Scholar
- 20.Bardin T, Karra RG, So A, et al. Lesinurad (LESU) adjunctive therapy with allopurinol (ALLO) in patients not responding to ALLO monotherapy: pooled post hoc safety and efficacy analysis in a patient subgroup using concomitant diuretics at baseline (BL) [abstract no. SAT0374]. Ann Rheum Dis. 2018;77(Suppl 2):1050.Google Scholar
- 21.Bardin T, Dalbeth N, Terkeltaub R, et al. Clinical response of tophus and flares to extended use of lesinurad in combination with a xanthine oxidase inhibitor in patients with gout [abstract no. 209]. Arthritis Rheumatol. 2016;68(Suppl 10).Google Scholar
- 23.Terkeltaub R, Saag KG, Goldfarb DS, et al. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. Rheumatology. 2018. https://doi.org/10.1093/rheumatology/key245.
- 24.Terkeltaub R, Malamet R, Bos K, et al. Renal safety of lesinurad: a pooled analysis of phase III and extension studies [abstract no. THU0455]. Ann Rheum Dis. 2017;76 (Suppl 2):379–80.Google Scholar
- 25.Klein RW, Kabadi S, Cinfio FN, et al. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective. J Comp Eff Res. 2018. https://doi.org/10.2217/cer-2017-0103.
- 27.Perez-Ruiz F, Kandaswamy P, Karra Gurunath R, et al. A summary of clinical evidence for commonly used uricosurics for gout in Europe [abstract no. SAT0360]. Ann Rheum Dis. 2018;77(Suppl 2):1045.Google Scholar